GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

AnGes 4563.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

27

+8.00%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About AnGes

Its shares trade on Tokyo Stock Exchange under the ticker 4563.T. It has been listed since 25 September 2002. In the fiscal year to 31 December 2025, it reported revenue of ¥874.1m and a net loss of ¥5.12bn. At that date it held total assets of ¥5.41bn and shareholders' equity of ¥3.08bn.

AnGes, Inc. engages in the research and development of gene-based medical products. The company is headquartered in Ibaraki-Shi, Osaka-Fu. The company went IPO on 2002-09-25. The firm is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
25 Sept 2002
Employees
36
Website
anges.co.jp ↗

Leadership

Pay as last reported

  • Mr. Ei YamadaPresident, Executive President, Chief Executive Officer, President of Subsidiary, Representative Director, since 2002
  • Mr. Naoya SatoDirector of Business Planning, Director, since 2022
  • Mr. Norikazu EikiIndependent Director
  • Mr. Makoto HaraIndependent Director
  • Mr. Junichi KomamuraIndependent Director
  • Ms. Kimiko MurofushiIndependent Director
  • Mr. Jun SakuraiDirector of Accounting, since 2017

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • AnGes Inc has a strong and experienced management team.
  • The company has a strong portfolio of intellectual property and patents.
  • AnGes Inc has a well-established brand reputation in the industry.

Weaknesses

  • AnGes Inc has a limited product line and is heavily dependent on a few key products.
  • The company has a small market share compared to its competitors.
  • AnGes Inc faces challenges in terms of scalability and expanding into new markets.

Opportunities

  • There is a growing demand for the company's products in the healthcare industry.
  • AnGes Inc can explore partnerships and collaborations to expand its reach.
  • The company can invest in research and development to develop new innovative products.

Threats

  • Increasing competition from other companies in the market poses a threat to AnGes Inc.
  • Regulatory changes and strict compliance requirements can impact the company's operations.
  • Fluctuating market conditions and economic factors can affect the overall demand for AnGes Inc's products.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.